title: [Pharmacokinetic profile of silodosin in clinical practice].
authors.affiliation: Clinical Development Planning, Planning & Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan. tomoji_shimizu@pharm.kissei.co.jp
authors.forename: Tomoji
authors.initials: T
authors.lastname: Shimizu
authors.forename: Itaru
authors.initials: I
authors.lastname: Miyashita
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Matsubara
authors.forename: Mitsugu
authors.initials: M
authors.lastname: Ikeda
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yamaguchi
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D001682:Biological Availability; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D018565:Food-Drug Interactions; D006160:Guanosine Triphosphate / Q000502:physiology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D007674:Kidney Diseases / Q000378:metabolism; D008297:Male; D009961:Orosomucoid / Q000378:metabolism; D011485:Protein Binding
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D007211:Indoles; D009961:Orosomucoid; D006160:Guanosine Triphosphate; D003577:Cytochrome P-450 Enzyme System; C095285:silodosin; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A